

GLAXOSMITHKLINE PLC  
Form 6-K  
October 14, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 14 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')  
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£17.0491	38
n/a (single transaction)	
  - d) Aggregated information
 

Aggregated volume	Price
-------------------	-------
  - e) Date of the transaction 2016-10-13
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.						
c) Price(s) and volume(s)	<table border="0"> <tr> <td style="padding-right: 20px;">Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.0491</td> <td>47</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </table>	Price(s)	Volume(s)	£17.0491	47	n/a (single transaction)	
Price(s)	Volume(s)						
£17.0491	47						
n/a (single transaction)							

d) Aggregated information  
Aggregated volume Price

e) Date of the transaction	2016-10-13
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2016, on shares held  
through the Company's  
ShareReward Plan.

c)	Price(s) and volume(s)	Price(s) £17.0491	Volume(s) 15
----	---------------------------	----------------------	-----------------

n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e)	Date of the transaction	2016-10-13
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance

c)	Initial notification/ amendment	Initial notification
----	------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
----	---	---

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
----	---------------------------	---

c)	Price(s) and volume(s)	Price(s) £17.0491	Volume(s) 5
----	---------------------------	----------------------	----------------

d) Aggregated information n/a (single transaction)

Aggregated volume Price

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain  
 b) Position/status President, Global  
 Pharmaceuticals

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 £17.0491 9  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern  
 b) Position/status Chief Strategy Officer  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£17.0491	53
n/a (single transaction)	
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2016-10-13
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the

re-investment of dividends  
paid to shareholders on 13  
October 2016, on shares held  
through the Company's  
ShareReward Plan.

c)	Price(s) and volume(s)	Price(s) £17.0491	Volume(s) 53
		n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e)	Date of the transaction	2016-10-13
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr P C Thomson
b)	Position/status	SVP, Communications & Government Affairs

c)	Initial notification/ amendment	Initial notification
----	------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
----	---	--

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
----	---------------------------	---

c)	Price(s) and volume(s)	Price(s) £17.0491	Volume(s) 28
d)	Aggregated information	n/a (single transaction)	

Aggregated volume Price

e) Date of the transaction 2016-10-13  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Dr P J T Vallance  
b) Position/status President, Pharmaceuticals  
R&D

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 13  
October 2016, on shares held  
through the Company's  
ShareReward Plan.

c) Price(s) and Volume(s)  
volume(s) £17.0491 31  
n/a (single transaction)

d) Aggregated information  
Aggregated volume Price

e) Date of the transaction 2016-10-13  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Ms E Walmsley  
b) Position/status CEO Designate



- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£17.0491 10  
n/a (single transaction)
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.	
c) Price(s) and volume(s)	Price(s) £17.0491 n/a (single transaction)	Volume(s) 37
d) Aggregated information Aggregated volume Price		
e) Date of the transaction	2016-10-13	
f) Place of the transaction	London Stock Exchange (XLON)	

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 14, 2016

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc